Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Anti-G17 immunogen: Phase II

Interim data from a 22-patient U.K. trial showed that

Read the full 95 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE